Bell J, Davies E, Brereton C, Vukmirovic M, Roberts J, Lunn K, Wickens L, Conforti F, Ridley R, Ceccato J, Sayer L, Johnston D, Vallejo A, Alzetani A, Jogai S, Marshall B, Fabre A, Richeldi L, Monk P, Skipp P, Kaminski N, Offer E, Wang Y, Davies D, Jones M. Spatial transcriptomic validation of a biomimetic model of fibrosis enables re-evaluation of a therapeutic antibody targeting LOXL2. Cell Reports Medicine 2024, 5: 101695. PMID: 39173635, PMCID: PMC11524965, DOI: 10.1016/j.xcrm.2024.101695.Peer-Reviewed Original Research